Media

Race Oncology Limited (ASX: RAC) (Race) is pleased to release an updatedinvestor presentation and invite investors to join a special online investor briefing. Updated Presentation Investor Briefing Invitation Investors are invited to attend a special briefing session where Managing Director and CEO, Phillip Lynch and CSO and Executive Director, Dr Daniel Tillett will discuss progress…

Race Oncology Limited (“Race”) is pleased to announce that it has entered into a collaborative preclinical research program with The University of Newcastle to investigate the heart safety Bisantrene offers over current anthracycline therapeutics. Eminent cardiotoxicity researchers, Associate Professors Aaron Sverdlov and Doan Ngo of the University of Newcastle, will lead the project. While Bisantrene’s…

20 April 2021 – Race Oncology Limited (“Race”) is pleased to announce the appointment of Dr David Fuller as Chief Medical Officer (CMO). This appointment follows the announcement by Race on 19 February 2021 that the Company would be recruiting a full-time, Australian- based CMO to drive its three-pillar strategy forward. An internationally experienced biopharmaceutical…

16 April 2021 – Race Oncology Limited (“Race”) is pleased to advise that it has appointed Professor Jianjun Chen of the City of Hope Hospital, Los Angeles, to its Scientific Advisory Board (SAB). I would like to thank Race Oncology for their kind invitation. I am so glad to serve on the Race Oncology SAB.…

15 April 2021 – Race Oncology Limited (“Race”) is pleased to share details of a recent scientific publication in the prestigious journal Nature Communication, confirming Bisantrene is a highly effective inhibitor of the Fat Mass and Obesity associated protein (FTO)1. This independent work was performed by a research team at the University of Chicago led…

31 March 2021 – Race Oncology Limited (“Race”) is pleased to update our shareholders on progress of our clinical and preclinical programs under the Three Pillars strategy, originally outlined at the Annual General Meeting of shareholders on 30 November 2020. Today’s update confirms committed and planned programs to maximise the significant opportunity offered by Bisantrene…

Race Oncology Limited (“Race”) is pleased to announce that it has entered into a new collaborative preclinical research program with The University of Newcastle. This work will be led by the eminent cancer researcher, Associate Professor Nikki Verrills, who successfully ran Race’s preclinical breast and ovarian program (ASX announcements: 24 November 2020, 23 February 2021,…

Race Oncology Limited (“Race”) is pleased to announce that it has entered into a new collaborative preclinical research program with The University of Newcastle. The work will be led by eminent cancer researcher, Associate Professor Nikki Verrills, who successfully ran Race’s preclinical breast and ovarian cancer programs (ASX announcements: 24 November 2020, 23 February 2021,…

19 March 2021 – Race Oncology Limited (“Race”) is pleased to announce that it has entered into a collaborative preclinical research program with The University of Newcastle. Eminent melanoma cancer researchers, Professor Xu Dong Zhang and Associate Professor Lei Jin will lead the project. The aim of this project is to explore the use of…